The purpose of this study is to evaluate the safety and tolerability of a single dose of
HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses
of HMPL-689 in healthy volunteers
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
Unknown status
Hutchison Medipharma Limited
Phase 1
This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma
for whom failed of standard care or have no standard of care.This study will consist of a
dose escalation stage (Stage I) and a dose expansion stage (Stage II).
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Recruiting
Hutchison Medipharma Limited
Phase 1
An open-label, dose escalation and expansion clinical trial to evaluate the safety,
tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Recruiting
Hutchison Medipharma Limited
Phase 2
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of
HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular
Lymphoma (FL)
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Not yet recruiting
Hutchmed
Phase 2
A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R
lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase
(phase IIb).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
